Literature DB >> 6126151

A variant form of metachromatic leukodystrophy without arylsulfatase deficiency.

A F Hahn, B A Gordon, G G Hinton, J J Gilbert.   

Abstract

The clinical, pathological, and biochemical findings in a young woman with a new variant of metachromatic leukodystrophy (MLD) are reported. The patient showed slow early development and deteriorated further during her first two decades. Nerve conductions were slow, and a sural nerve biopsy showed features of a sulfatide lipidosis. Urinary sulfatide excretion was comparable to that of patients with classic MLD, yet in vitro activity of arylsulfatase A and B and cerebroside sulfatase activity were normal. Skin fibroblasts cultured in medium supplemented with 3H-labeled sulfatide showed accumulation of labeled sulfatide in large amounts, implying a defect in sulfatide hydrolysis in vivo in spite of intact enzyme activity in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126151     DOI: 10.1002/ana.410120106

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Peripheral neuropathy in metachromatic leucodystrophy. A study of 40 cases from south India.

Authors:  P S Bindu; A Mahadevan; A B Taly; R Christopher; N Gayathri; S K Shankar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

2.  Late-onset Krabbe disease initially diagnosed as cerebroside sulfatase activator deficiency.

Authors:  A L Fluharty; L Neidengard; D Holtzman; H Kihara
Journal:  Metab Brain Dis       Date:  1986-09       Impact factor: 3.584

3.  Insertion in the mRNA of a metachromatic leukodystrophy patient with sphingolipid activator protein-1 deficiency.

Authors:  X L Zhang; M A Rafi; G DeGala; D A Wenger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study.

Authors:  W Schlote; K Harzer; H Christomanou; B C Paton; B Kustermann-Kuhn; B Schmid; J Seeger; U Beudt; I Schuster; U Langenbeck
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

5.  The mechanism for a 33-nucleotide insertion in mRNA causing sphingolipid activator protein (SAP-1)-deficient metachromatic leukodystrophy.

Authors:  X L Zhang; M A Rafi; G DeGala; D A Wenger
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

6.  Immunocytochemical localization of sphingolipid activator protein-1, the sulfatide/GM1 ganglioside activator, to lysosomes in human liver and colon.

Authors:  T Tamaru; S Fujibayashi; W R Brown; D A Wenger
Journal:  Histochemistry       Date:  1986

7.  Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.

Authors:  B Schmid; B C Paton; K Sandhoff; K Harzer
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

8.  The AB-variant of metachromatic leukodystrophy (postulated activator protein deficiency). Light and electron microscopic findings in a sural nerve biopsy.

Authors:  A F Hahn; B A Gordon; J J Gilbert; G G Hinton
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

9.  Correction of sulfatide metabolism after transfer of prosaposin cDNA to cultured cells from a patient with SAP-1 deficiency.

Authors:  M A Rafi; S Amini; X L Zhang; D A Wenger
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

10.  Genetic complementation in somatic cell hybrids of cerebroside sulfatase activator deficiency and metachromatic leukodystrophy fibroblasts.

Authors:  H Kihara; K K Tsay; A L Fluharty
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.